Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.
Cardiac amyloidosis
Epidemiology
Hypertrophy
Prevalence
Transthyretin amyloid cardiomyopathy
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
revised:
22
06
2024
received:
30
04
2024
accepted:
28
06
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
30
8
2024
Statut:
aheadofprint
Résumé
Recognition of transthyretin amyloid cardiomyopathy is increasing due to advances in cardiac imaging and diagnostic strategies, but questions remain regarding disease frequency and characteristics. We examined the prevalence and characteristics of transthyretin amyloid cardiomyopathy in older patients with hypertrophic cardiomyopathy of unascertained aetiology. TTRACK was a multicentre, non-interventional, cross-sectional epidemiologic study funded by Pfizer and conducted in 20 hospitals and medical centres in 11 countries (NCT03842163). Eligible patients were aged ≥50 years, had hypertrophic cardiomyopathy (maximal end-diastolic left ventricular wall thickness ≥15 mm on echocardiogram) without an identified genetic or alternative origin at study enrolment, and underwent In the TTRACK study, almost one in five patients ≥50 years of age with hypertrophic cardiomyopathy had transthyretin amyloid cardiomyopathy. Greater awareness of the frequency and characteristics of transthyretin amyloid cardiomyopathy in older patients with hypertrophic cardiomyopathy are needed to help improve early detection of this debilitating but treatable disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pfizer
Informations de copyright
© 2024 Pfizer Inc. and The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state‐of‐the‐art review. J Am Coll Cardiol 2019;73:2872‐2891. doi:10.1016/j.jacc.2019.04.003
González‐López E, Gagliardi C, Dominguez F, Quarta CC, de Haro‐Del Moral FJ, Milandri A, et al. Clinical characteristics of wild‐type transthyretin cardiac amyloidosis: Disproving myths. Eur Heart J 2017;38:1895‐1904. doi:10.1093/eurheartj/ehx043
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild‐type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016;68:1014‐1020. doi:10.1016/j.jacc.2016.06.033
Gonzalez‐Lopez E, Escobar‐Lopez L, Obici L, Saturi G, Bezard M, Saith SE, et al. Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms. JACC CardioOncol 2022;4:442‐454. doi:10.1016/j.jaccao.2022.07.007
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez‐Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39:2799‐2806. doi:10.1093/eurheartj/ehx589
Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 2022;146:1657‐1670. doi:10.1161/circulationaha.122.060852
Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail 2019;7:709‐716. doi:10.1016/j.jchf.2019.04.010
Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient with Cardiac Amyloidosis: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2023;81:1076‐1126. doi:10.1016/j.jacc.2022.11.022
Garcia‐Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554‐1568. doi:10.1093/eurheartj/ehab072
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733‐2779. doi:10.1093/eurheartj/ehu284
Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc‐3,3‐diphosphono‐1,2‐propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076‐1084. doi:10.1016/j.jacc.2005.05.073
Long TE, Indridason OS, Palsson R, Rognvaldsson S, Love TJ, Thorsteinsdottir S, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. Blood Cancer J 2022;12:133. doi:10.1038/s41408‐022‐00732‐3
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2‐evidence base and standardized methods of imaging. J Card Fail 2019;25:e1‐e39. doi:10.1016/j.cardfail.2019.08.001
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2‐diagnostic criteria and appropriate utilization. J Card Fail 2019;25:854‐865. doi:10.1016/j.cardfail.2019.08.002
Damy T, Costes B, Hagège AA, Donal E, Eicher JC, Slama M, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J 2016;37:1826‐1834. doi:10.1093/eurheartj/ehv583
Lopes LR, Futema M, Akhtar MM, Lorenzini M, Pittman A, Syrris P, et al. Prevalence of TTR variants detected by whole‐exome sequencing in hypertrophic cardiomyopathy. Amyloid 2019;26:243‐247. doi:10.1080/13506129.2019.1665996
Maurizi N, Rella V, Fumagalli C, Salerno S, Castelletti S, Dagradi F, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 2020;300:191‐195. doi:10.1016/j.ijcard.2019.07.051
González‐López E, Gallego‐Delgado M, Guzzo‐Merello G, de Haro‐Del Moral FJ, Cobo‐Marcos M, Robles C, et al. Wild‐type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585‐2594. doi:10.1093/eurheartj/ehv338
Lindmark K, Pilebro B, Sundström T, Lindqvist P. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail 2021;8:745‐749. doi:10.1002/ehf2.13110
AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 2021;6:1267‐1274. doi:10.1001/jamacardio.2021.3070
Merlo M, Pagura L, Porcari A, Cameli M, Vergaro G, Musumeci B, et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey. Eur J Heart Fail 2022;24:1377‐1386. doi:10.1002/ejhf.2504
Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies. Eur J Heart Fail 2022;24:2342‐2351. doi:10.1002/ejhf.2532
Kharoubi M, Bézard M, Galat A, Le Bras F, Poullot E, Molinier‐Frenkel V, et al. History of extracardiac/cardiac events in cardiac amyloidosis: Prevalence and time from initial onset to diagnosis. ESC Heart Fail 2021;8:5501‐5512. doi:10.1002/ehf2.13652
Ton VK, Mukherjee M, Judge DP. Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction. Clin Med Insights Cardiol 2014;8:39‐44. doi:10.4137/cmc.S15719
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404‐2412. doi:10.1161/circulationaha.116.021612
Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015;66:2451‐2466. doi:10.1016/j.jacc.2015.09.075
Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: An update on diagnosis and treatment. ESC Heart Fail 2019;6:1128‐1139. doi:10.1002/ehf2.12518
Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med 2018;28:10‐21. doi:10.1016/j.tcm.2017.07.004
Davies DR, Redfield MM, Scott CG, Minamisawa M, Grogan M, Dispenzieri A, et al. A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 2022;7:1036‐1044. doi:10.1001/jamacardio.2022.1781
Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203‐1212. doi:10.1161/circulationaha.108.843334
Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, et al. Carpal tunnel syndrome: A common initial symptom of systemic wild‐type ATTR (ATTRwt) amyloidosis. Amyloid 2016;23:58‐63. doi:10.3109/13506129.2015.1135792
Fosbøl EL, Rørth R, Leicht BP, Schou M, Maurer MS, Kristensen SL, et al. Association of carpal tunnel syndrome with amyloidosis, heart failure, and adverse cardiovascular outcomes. J Am Coll Cardiol 2019;74:15‐23. doi:10.1016/j.jacc.2019.04.054
Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail 2020;22:507‐515. doi:10.1002/ejhf.1742
Arana‐Achaga X, Goena‐Vives C, Villanueva‐Benito I, Solla‐Ruiz I, Rengel Jimenez A, Gaspar TI, et al. Development and validation of a prediction model and score for transthyretin cardiac amyloidosis diagnosis: T‐Amylo. JACC Cardiovasc Imaging 2023;16:1567‐1580. doi:10.1016/j.jcmg.2023.05.002
Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016;68:161‐172. doi:10.1016/j.jacc.2016.03.596
Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age‐related cardiac amyloid disease associated with wild‐type transthyretin: A prospective, observational cohort study. Circulation 2016;133:282‐290. doi:10.1161/circulationaha.115.018852
Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, et al. Senile systemic amyloidosis: Clinical features at presentation and outcome. J Am Heart Assoc 2013;2:e000098. doi:10.1161/jaha.113.000098
Bruno M, Castaño A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: Frequency, characteristics, and diagnostic challenges. Heart Fail Rev 2021;26:35‐45. doi:10.1007/s10741‐020‐10010‐8
Olson LJ, Gertz MA, Edwards WD, Li CY, Pellikka PA, Holmes DR Jr, et al. Senile cardiac amyloidosis with myocardial dysfunction. Diagnosis by endomyocardial biopsy and immunohistochemistry. N Engl J Med 1987;317:738‐742. doi:10.1056/nejm198709173171205